☆ 4.6 Article

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England

L. Hounsome et al.

Summary: The study investigated treatment and outcome patterns in diffuse large B-cell lymphoma patients aged 65 and older, revealing a better survival rate associated with the NHS urgent cancer pathway. Equivalent survival rates between R-CHOP and R-mini-CHOP were found in patients aged 80 and older.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Herve Tilly et al.

Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy of Ibrutinib, Rituximab and Mini -CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Emma Verner et al.

BLOOD (2021)

Add to Collection

Article Oncology

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

Lucie Oberic et al.

Summary: The prognosis of elderly patients with DLBCL is worse than that of young patients. An attenuated dose of chemotherapy and addition of lenalidomide does not significantly improve overall survival compared to standard treatment.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy

Junichi Nakagawa et al.

Summary: This study found that elderly patients aged 80 years and older receiving (R-)miniCHOP therapy may have lower AUCs of DXR and CPA compared to those receiving (R-)CHOP therapy, with a similar trend seen for VCR but not significant.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi

Francesco Merli et al.

Summary: The study prospectively validated the use of a simplified geriatric assessment (sGA) for older patients with DLBCL and developed a new Elderly Prognostic Index (EPI) based on the sGA groups, International Prognostic Index, and hemoglobin levels to predict overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings et al.

Summary: This study aimed to evaluate the safety and recommended dose of a novel bispecific antibody epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results showed that the full dose of 48 mg was identified as the recommended phase 2 dose, and no maximum tolerated dose was reached during the treatment. Epcoritamab demonstrated good antitumor activity in some patients during the study.

LANCET (2021)

Add to Collection

Article Hematology

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Mirian Brink et al.

Summary: The study investigated whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. Results showed that the 3-year OS did not differ between patients treated with R-originator or R-biosimilars, supporting the use of R-biosimilars in DLBCL treatment management.

BLOOD ADVANCES (2021)

Add to Collection

Meeting Abstract Hematology

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski et al.

BLOOD (2020)

Add to Collection

Article Oncology

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

E. Baudry et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)

Add to Collection

Article Oncology

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Hematology

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

Sergio Storti et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Hematology

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

Sergio Storti et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Hematology

Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial

Qiu-Dan Shen et al.

LANCET HAEMATOLOGY (2018)

Add to Collection

Article Hematology

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

Frederic Peyrade et al.

LANCET HAEMATOLOGY (2017)

Add to Collection

Article Hematology

R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma

Kamel Laribi et al.

ANNALS OF HEMATOLOGY (2016)

Add to Collection

Article Oncology

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

Gareth J. Veal et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Article Oncology

Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology

Andrew D. Zelenetz et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)

Add to Collection

Article Oncology

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro

H. Tilly et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network

A. Smith et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Frederic Peyrade et al.

LANCET ONCOLOGY (2011)

Add to Collection

Article Mathematics, Interdisciplinary Applications

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

Peter C. Austin

MULTIVARIATE BEHAVIORAL RESEARCH (2011)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG

Markus Joerger et al.

CLINICAL PHARMACOKINETICS (2007)

Add to Collection

Article Nutrition & Dietetics

Longitudinal changes in body composition in older men and women: role of body weight change and physical activity

VA Hughes et al.

AMERICAN JOURNAL OF CLINICAL NUTRITION (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.